Accustem Sciences (ACUT) Stock Overview

AccuStem Sciences, Inc., an early-stage life sciences company, focuses on developing and commercializing products for the treatment and management of various cancers. The company's genomics-based personalized medicine business primarily focuses on breast and lung cancer patients. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York.